Assertio Holdings, Inc.

Fourth quarter 2025 total product sales were $12.8 million versus $29.6 million in the prior-year quarter. Robodon net sales were $0.4 million versus $15.4 million a year ago, SYMPAZAN sales were $3.1 million versus $2.5 million, and Indocin sales were $5.5 million, flat year over year. Q4 gross margin was 75% versus 61% last year, SG&A was $13.1 million versus $21.4 million, GAAP net loss was $11.9 million versus a loss of $10.5 million, and adjusted EBITDA was negative $4.1 million versus positive $3.4 million. Full-year 2025 product sales were $117.1 million, Robodon sales were $68.2 million versus $60.1 million, Indocin sales were $18.9 million, gross margin was 70% versus 68%, and adjusted EBITDA was $22.7 million versus $18.3 million. Cash, cash equivalents, and short-term investments were $63.4 million at 12/31/2025 versus $93.4 million at 9/30/2025. For fiscal 2026, management guided to revenue of $110 million to $125 million and adjusted EBITDA of $28 million to $40 million.

Mark Reisenauer framed the quarter around three priorities: scaling Robodon, using Assertio’s commercial platform more broadly in oncology, and being more disciplined with capital allocation. He said the company’s prior strategy of acquiring on-market specialty products is no longer capital efficient, and he specifically cited SYMPAZAN as an example where incremental investment is not justified. His tone was confident but selective: he emphasized a solid balance sheet, a meaningful runway for Robodon, and a more focused approach to business development.

Ajay Patel emphasized that Q4 and 2025 results were shaped by the Robodon sell-in and the related working-capital swing. He said the cash decline to $63.4 million was mainly due to higher accounts receivable and accrued rebates tied to the transition, and he expects working capital and cash flows to normalize by April, when newly labeled Robodon sales should begin in Q2. On margins, he highlighted Q4 gross margin of 75% and full-year gross margin of 70%, and he said 2026 adjusted EBITDA should benefit from high-margin Robodon growth and structural cost savings, including reduced litigation expense, decommercialization of OTREXUP, and a leaner personnel structure.

Analysts pressed for detail on what oncology assets Assertio would pursue, and management said it is looking primarily at on-market and late-stage development assets, mostly therapeutics, with a small incremental investment likely required on top of the existing commercial base. Questions also focused on Robodon’s 2026 growth mechanics; management said it expects no channel inventory build, with quarterly demand generally aligned with shipments, and sees growth coming mainly from new accounts and further penetration in community oncology/Medicare Part B. On Indocin, management said it expects at least one additional generic in 2026 and therefore expects year-over-year decline. They also said the upper end of 2026 guidance still assumes some erosion in Indocin.